Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global Neuroblastoma Drugs Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 Chemotherapy
  • 1.4.3 Immunotherapy
  • 1.4.4 Others
• 1.5 Market by Application
  • 1.5.1 Global Neuroblastoma Drugs Market Share by Application (2014-2025)
  • 1.5.2 Hospitals
  • 1.5.3 Clinics
  • 1.5.4 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Neuroblastoma Drugs Market Size
• 2.2 Neuroblastoma Drugs Growth Trends by Regions
  • 2.2.1 Neuroblastoma Drugs Market Size by Regions (2014-2025)
  • 2.2.2 Neuroblastoma Drugs Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Opportunities

3 Market Share by Key Players

• 3.1 Neuroblastoma Drugs Market Size by Manufacturers
  • 3.1.1 Global Neuroblastoma Drugs Revenue by Manufacturers (2014-2019)
  • 3.1.2 Global Neuroblastoma Drugs Revenue Market Share by Manufacturers (2014-2019)
  • 3.1.3 Global Neuroblastoma Drugs Market Concentration Ratio (CR5 and HHI)
• 3.2 Neuroblastoma Drugs Key Players Head office and Area Served
• 3.3 Key Players Neuroblastoma Drugs Product/Solution/Service
• 3.4 Date of Enter into Neuroblastoma Drugs Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global Neuroblastoma Drugs Market Size by Type (2014-2019)
• 4.2 Global Neuroblastoma Drugs Market Size by Application (2014-2019)

5 United States

• 5.1 United States Neuroblastoma Drugs Market Size (2014-2019)
• 5.2 Neuroblastoma Drugs Key Players in United States
• 5.3 United States Neuroblastoma Drugs Market Size by Type
• 5.4 United States Neuroblastoma Drugs Market Size by Application

6 Europe

• 6.1 Europe Neuroblastoma Drugs Market Size (2014-2019)
• 6.2 Neuroblastoma Drugs Key Players in Europe
• 6.3 Europe Neuroblastoma Drugs Market Size by Type
• 6.4 Europe Neuroblastoma Drugs Market Size by Application

7 China

• 7.1 China Neuroblastoma Drugs Market Size (2014-2019)
• 7.2 Neuroblastoma Drugs Key Players in China
• 7.3 China Neuroblastoma Drugs Market Size by Type
• 7.4 China Neuroblastoma Drugs Market Size by Application

8 Japan

• 8.1 Japan Neuroblastoma Drugs Market Size (2014-2019)
• 8.2 Neuroblastoma Drugs Key Players in Japan
• 8.3 Japan Neuroblastoma Drugs Market Size by Type
• 8.4 Japan Neuroblastoma Drugs Market Size by Application

9 Southeast Asia

• 9.1 Southeast Asia Neuroblastoma Drugs Market Size (2014-2019)
• 9.2 Neuroblastoma Drugs Key Players in Southeast Asia
• 9.3 Southeast Asia Neuroblastoma Drugs Market Size by Type
• 9.4 Southeast Asia Neuroblastoma Drugs Market Size by Application

10 India

• 10.1 India Neuroblastoma Drugs Market Size (2014-2019)
• 10.2 Neuroblastoma Drugs Key Players in India
• 10.3 India Neuroblastoma Drugs Market Size by Type
• 10.4 India Neuroblastoma Drugs Market Size by Application

11 Central & South America

• 11.1 Central & South America Neuroblastoma Drugs Market Size (2014-2019)
• 11.2 Neuroblastoma Drugs Key Players in Central & South America
• 11.3 Central & South America Neuroblastoma Drugs Market Size by Type
• 11.4 Central & South America Neuroblastoma Drugs Market Size by Application

12 International Players Profiles

• 12.1 Pfizer
  • 12.1.1 Pfizer Company Details
  • 12.1.2 Company Description and Business Overview
  • 12.1.3 Neuroblastoma Drugs Introduction
  • 12.1.4 Pfizer Revenue in Neuroblastoma Drugs Business (2014-2019)
  • 12.1.5 Pfizer Recent Development
• 12.2 Teva Pharmaceutical
  • 12.2.1 Teva Pharmaceutical Company Details
  • 12.2.2 Company Description and Business Overview
  • 12.2.3 Neuroblastoma Drugs Introduction
  • 12.2.4 Teva Pharmaceutical Revenue in Neuroblastoma Drugs Business (2014-2019)
  • 12.2.5 Teva Pharmaceutical Recent Development
• 12.3 Johnson & Johnson
  • 12.3.1 Johnson & Johnson Company Details
  • 12.3.2 Company Description and Business Overview
  • 12.3.3 Neuroblastoma Drugs Introduction
  • 12.3.4 Johnson & Johnson Revenue in Neuroblastoma Drugs Business (2014-2019)
  • 12.3.5 Johnson & Johnson Recent Development
• 12.4 Bristol-Myers Squibb
  • 12.4.1 Bristol-Myers Squibb Company Details
  • 12.4.2 Company Description and Business Overview
  • 12.4.3 Neuroblastoma Drugs Introduction
  • 12.4.4 Bristol-Myers Squibb Revenue in Neuroblastoma Drugs Business (2014-2019)
  • 12.4.5 Bristol-Myers Squibb Recent Development
• 12.5 United Therapeutics
  • 12.5.1 United Therapeutics Company Details
  • 12.5.2 Company Description and Business Overview
  • 12.5.3 Neuroblastoma Drugs Introduction
  • 12.5.4 United Therapeutics Revenue in Neuroblastoma Drugs Business (2014-2019)
  • 12.5.5 United Therapeutics Recent Development

13 Market Forecast 2019-2025

• 13.1 Market Size Forecast by Regions
• 13.2 United States
• 13.3 Europe
• 13.4 China
• 13.5 Japan
• 13.6 Southeast Asia
• 13.7 India
• 13.8 Central & South America
• 13.9 Market Size Forecast by Product (2019-2025)
• 13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 12.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Disclaimer

Neuroblastoma (NB) is a type of cancer that forms in certain types of nerve tissue. It most frequently starts from one of the adrenal glands, but can also develop in the neck, chest, abdomen, or spine. Symptoms may include bone pain, a lump in the abdomen, neck, or chest, or a painless bluish lump under the skin.
In 2018, the global Neuroblastoma Drugs market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Neuroblastoma Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Neuroblastoma Drugs development in United States, Europe and China.

The key players covered in this study
Pfizer
Teva Pharmaceutical
Johnson & Johnson
Bristol-Myers Squibb
United Therapeutics
...

Market segment by Type, the product can be split into
Chemotherapy
Immunotherapy
Others

Market segment by Application, split into
Hospitals
Clinics
Others

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Neuroblastoma Drugs status, future forecast, growth opportunity, key market and key players.
To present the Neuroblastoma Drugs development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Neuroblastoma Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.